search buttonmobile navigation expand button

Back to Search Results

Dr. Aniel Majjhoo, interventional neurologist, invited to participate in international clinical trial

Published on Thursday, September 21, 2017
Dr. Aniel Majjhoo

MOUNT CLEMENS, Mich.—McLaren Macomb interventional neurologist Dr. Aniel Majjhoo has been invited to participate in NAVIGATE ESUS (embolic stroke of undetermined source), the international clinical trial aimed to study recent stroke patients whose source of stroke could not be determined.

The purpose of the trial is to compare blood thinners in recent stroke patients whose stroke attack was brought upon by an unknown origin.

“An invitation to take part in this international research trial speaks volumes of our neuroscience program,” said Dr. Majjhoo, also the medical director of the McLaren Macomb Neuroscience Institute. “Being able to contribute to NAVIGATE ESUS is credit to our program and its reputation.”

Comprising one-third of all strokes, NAVIGATE ESUS aims to determine if the frequency of cryptogenic embolic strokes can be reduced by taking certain blood thinners. In order to decide if this is a viable preventative treatment, Dr. Majjhoo and other physicians taking part in the trial must determine if this treatment is effective.

“Clinical trials are instrumental in improving the care provided by the physicians throughout the entire healthcare industry,” said Bernice Edwin, MPH, clinical research associate with McLaren Macomb. “For a life changing condition like stroke, being part of a clinical trial which aims at lessening the occurrence of stroke, is a compliment to our program.”

Embolic strokes are caused by a blood clot, formed somewhere within the body, that travels to the brain, depriving it of oxygen-rich blood.

The fifth leading cause of death and the leading cause of adult disability in the United States, 795,000 people suffer a stroke each year. On average, there is one stroke every 40 seconds. McLaren Macomb, part of the McLaren Stroke Network, provides 24/7 initial evaluations by the interventional neurologists for all suspected-stroke patients.

To learn more about The Joint Commission certified stroke program at McLaren Macomb, visit

About McLaren Macomb
In January 2012, Mount Clemens Regional Medical Center became McLaren Macomb.

McLaren Macomb is a 288-bed acute care hospital located in Mount Clemens, Mich. More than 400 physicians and nearly 2,000 employees work at McLaren Macomb making it one of Macomb County’s top employers. McLaren Macomb provides a full range of services, including cancer and cardiovascular care. As Macomb County’s first verified trauma center, the hospital operates the busiest emergency department in Macomb County and is also an accredited chest pain center. McLaren Macomb has a rich history of providing high quality, compassionate health care and holds a strong position in the community it serves. To learn more, visit or visit our blog at

About McLaren Health Care
McLaren Health Care, headquartered in Flint, Michigan, is a fully integrated health network committed to quality evidence-based patient care and cost efficiency. The McLaren system includes 12 hospitals, ambulatory surgery centers, imaging centers, the state’s only proton therapy center, an employed primary care physician network, commercial and Medicaid HMOs covering more than 250,000 lives, home health and hospice providers, retail medical equipment showrooms, pharmacy services, and a wholly owned medical malpractice insurance company. McLaren operates Michigan’s largest network of cancer centers and providers, anchored by Karmanos Cancer Institute, one of only two National Cancer Institute-designated comprehensive cancer centers in the state. McLaren has 21,000 employees and more than 25,000 network providers. Its operations are housed in more than 300 facilities serving a 54-county market and 75 percent of Michigan’s population. Learn more at